Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
Any hopes of differentiation could come down to side effects.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
